IDEXX Laboratories Inc. (IDXX)
| Bid | 404 |
| Market Cap | 32.78B |
| Revenue (ttm) | 3.9B |
| Net Income (ttm) | 887.87M |
| EPS (ttm) | 10.67 |
| PE Ratio (ttm) | 37.91 |
| Forward PE | 35.25 |
| Analyst | Buy |
| Ask | 404.82 |
| Volume | 705,022 |
| Avg. Volume (20D) | 834,162 |
| Open | 394.00 |
| Previous Close | 390.94 |
| Day's Range | 391.05 - 405.27 |
| 52-Week Range | 356.14 - 548.88 |
| Beta | 1.50 |
About IDXX
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic an...
Analyst Forecast
According to 8 analyst ratings, the average rating for IDXX stock is "Buy." The 12-month stock price forecast is $535, which is an increase of 32.26% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago · businesswire.com
IDEXX Laboratories to Release 2025 First Quarter Financial ResultsWESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 first quarter financial results for Thur...
4 weeks ago · seekingalpha.com
IDEXX Laboratories: Cancer Dx Launch In March 2025; Upgrading To 'Buy'Upgraded IDEXX to 'Buy' with a $450 price target due to oncology business expansion and share repurchase program. IDEXX's oncology market entry with Cancer Dx panel in March 2025 could drive significa...
